Tenax Therapeutics (TENX) EBIAT (2016)
Historic EBIAT for Tenax Therapeutics (TENX) over the last 6 years, with Q4 2016 value amounting to -$33.9 million.
- Tenax Therapeutics' EBIAT fell 17972.22% to -$33.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$54.9 million, marking a year-over-year increase of 6433.49%. This contributed to the annual value of -$17.6 million for FY2024, which is 12827.13% down from last year.
- Latest data reveals that Tenax Therapeutics reported EBIAT of -$33.9 million as of Q4 2016, which was down 17972.22% from -$4.3 million recorded in Q3 2016.
- In the past 5 years, Tenax Therapeutics' EBIAT registered a high of $107.6 million during Q2 2012, and its lowest value of -$117.0 million during Q2 2013.
- For the 4-year period, Tenax Therapeutics' EBIAT averaged around -$9.2 million, with its median value being -$4.6 million (2016).
- Examining YoY changes over the last 5 years, Tenax Therapeutics' EBIAT showed a top increase of 367659.93% in 2012 and a maximum decrease of 38687.41% in 2012.
- Tenax Therapeutics' EBIAT (Quarter) stood at -$1.6 million in 2012, then crashed by 7415.94% to -$117.0 million in 2013, then surged by 89.66% to -$12.1 million in 2015, then tumbled by 179.72% to -$33.9 million in 2016.
- Its EBIAT was -$33.9 million in Q4 2016, compared to -$4.3 million in Q3 2016 and -$4.6 million in Q2 2016.